[{"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-001", "question": "A 45-year-old man with autosomal dominant polycystic kidney disease presents with acute flank pain and hematuria. Imaging reveals a 6 cm cyst with internal septations and hemorrhage. Renal function is preserved, but he develops fever and leukocytosis. Blood cultures are negative, but cyst aspiration yields purulent fluid positive for Escherichia coli. Despite appropriate intravenous antibiotics, his symptoms persist. What is the most appropriate next step in management?", "options": ["Switch to a different antibiotic based on sensitivity testing", "Perform percutaneous cyst drainage and sclerotherapy", "Initiate long-term suppressive antibiotic therapy", "Surgical decortication of the infected cyst", "Administer intraparenchymal antibiotic infusion"], "answer": "D", "answer_index": 3, "explanation": "Surgical decortication is indicated for persistent cyst infection in polycystic kidney disease when antibiotics and drainage fail, as it allows complete removal of infected material. Percutaneous drainage often fails due to viscous cyst contents and multiloculation, while sclerotherapy is not appropriate for infected cysts. Long-term suppression or antibiotic switches do not address the source of ongoing infection.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified, tending toward M)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey stem clues: ADPKD; 6‑cm complex cyst with septations and hemorrhage; clear evidence of cyst infection (purulent aspirate, E. coli, fever, leukocytosis); blood cultures negative; renal function preserved; “despite appropriate IV antibiotics, his symptoms persist.” The stem does not state that any drainage has been attempted yet.\\n\\nCore management principle: For infected renal cysts in ADPKD not responding to systemic antibiotics, percutaneous drainage is typically the next interventional step; surgery is reserved when drainage is not feasible or fails. The explanation claims decortication is indicated “when antibiotics and drainage fail,” but the vignette never documents a drainage attempt.\\n\\nThus, both B (percutaneous drainage) and D (surgical decortication) are potentially defensible depending on the assumed practice sequence. With no mention that drainage has been tried or is impossible, D is not clearly superior and appears prematurely aggressive.\\n\\nMedical accuracy: The hierarchy of management (antibiotics → drainage → surgery) is standard; percutaneous drainage can be challenging in ADPKD but is still used. The explanation overstates the futility of drainage.\\n\\nMinimal fix: Add a line such as “Percutaneous drainage was attempted but failed to relieve symptoms” to justify D as clearly best, or change the key to B and adjust the explanation accordingly.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified, tending toward M)\nVerdict on keyed answer: Not uniquely determinable\n\nKey stem clues: ADPKD; 6‑cm complex cyst with septations and hemorrhage; clear evidence of cyst infection (purulent aspirate, E. coli, fever, leukocytosis); blood cultures negative; renal function preserved; “despite appropriate IV antibiotics, his symptoms persist.” The stem does not state that any drainage has been attempted yet.\n\nCore management principle: For infected renal cysts in ADPKD not responding to systemic antibiotics, percutaneous drainage is typically the next interventional step; surgery is reserved when drainage is not feasible or fails. The explanation claims decortication is indicated “when antibiotics and drainage fail,” but the vignette never documents a drainage attempt.\n\nThus, both B (percutaneous drainage) and D (surgical decortication) are potentially defensible depending on the assumed practice sequence. With no mention that drainage has been tried or is impossible, D is not clearly superior and appears prematurely aggressive.\n\nMedical accuracy: The hierarchy of management (antibiotics → drainage → surgery) is standard; percutaneous drainage can be challenging in ADPKD but is still used. The explanation overstates the futility of drainage.\n\nMinimal fix: Add a line such as “Percutaneous drainage was attempted but failed to relieve symptoms” to justify D as clearly best, or change the key to B and adjust the explanation accordingly.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-002", "question": "A 62-year-old woman with chronic lymphocytic leukemia develops petechiae and easy bruising. Laboratory studies show hemoglobin 9.2 g/dL, platelets 12,000/μL, and white blood cells 45,000/μL with 80% lymphocytes. Bone marrow biopsy reveals 90% infiltration by small lymphocytes. She has no active infection or bleeding. What is the most likely mechanism underlying her thrombocytopenia?", "options": ["Autoimmune destruction mediated by anti-platelet antibodies", "Bone marrow suppression from leukemic infiltration", "Hypersplenism with platelet sequestration", "Drug-induced thrombocytopenia from prior chemotherapy", "Microangiopathic hemolytic anemia with consumptive thrombocytopenia"], "answer": "B", "answer_index": 1, "explanation": "In advanced chronic lymphocytic leukemia, thrombocytopenia is primarily due to bone marrow infiltration by leukemic cells, crowding out normal hematopoiesis. Autoimmune thrombocytopenia occurs in only 1-2% of cases and typically responds to steroids, while hypersplenism is less common without massive splenomegaly. Drug effects or microangiopathy are not supported by the clinical scenario.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Long-standing CLL, very high lymphocyte count, bone marrow biopsy showing 90% small lymphocytic infiltration, thrombocytopenia (platelets 12,000/μL) with concurrent anemia and no acute infection, bleeding, drug history, or features of hemolysis or splenomegaly. These findings indicate advanced marrow failure due to leukemic infiltration, which impairs normal megakaryopoiesis and erythropoiesis.\\n\\nOption B (bone marrow suppression from leukemic infiltration) directly matches the provided marrow biopsy and is the classic mechanism of cytopenias in advanced-stage CLL. Option A (autoimmune destruction) is possible in CLL but is less common, not suggested by the marrow showing profound leukemic replacement, and autoimmune thrombocytopenia does not require such heavy marrow infiltration. C (hypersplenism) is not supported: no splenomegaly reported. D (drug-induced) lacks any chemotherapy history. E (microangiopathic hemolytic anemia) is inconsistent with no description of schistocytes, hemolysis, renal/neurologic findings.\\n\\nNo major medical inaccuracies are present; incidence data in the explanation are slightly off (autoimmune cytopenias more common than 1–2%) but do not affect the keyed mechanism.\\n\\nMinimal fix: Add a line explicitly stating “She has not yet received chemotherapy and has no splenomegaly” to further exclude D and C.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Long-standing CLL, very high lymphocyte count, bone marrow biopsy showing 90% small lymphocytic infiltration, thrombocytopenia (platelets 12,000/μL) with concurrent anemia and no acute infection, bleeding, drug history, or features of hemolysis or splenomegaly. These findings indicate advanced marrow failure due to leukemic infiltration, which impairs normal megakaryopoiesis and erythropoiesis.\n\nOption B (bone marrow suppression from leukemic infiltration) directly matches the provided marrow biopsy and is the classic mechanism of cytopenias in advanced-stage CLL. Option A (autoimmune destruction) is possible in CLL but is less common, not suggested by the marrow showing profound leukemic replacement, and autoimmune thrombocytopenia does not require such heavy marrow infiltration. C (hypersplenism) is not supported: no splenomegaly reported. D (drug-induced) lacks any chemotherapy history. E (microangiopathic hemolytic anemia) is inconsistent with no description of schistocytes, hemolysis, renal/neurologic findings.\n\nNo major medical inaccuracies are present; incidence data in the explanation are slightly off (autoimmune cytopenias more common than 1–2%) but do not affect the keyed mechanism.\n\nMinimal fix: Add a line explicitly stating “She has not yet received chemotherapy and has no splenomegaly” to further exclude D and C.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-003", "question": "A 28-year-old man with common variable immunodeficiency presents with recurrent sinopulmonary infections. Immunoglobulin levels show IgG 150 mg/dL, IgA <5 mg/dL, and IgM 20 mg/dL. He has absent responses to protein and polysaccharide vaccines. Genetic testing reveals a heterozygous mutation in the TACI gene. What is the most appropriate long-term management strategy?", "options": ["Monthly intravenous immunoglobulin replacement", "Prophylactic antibiotics with trimethoprim-sulfamethoxazole", "Hematopoietic stem cell transplantation", "Rituximab therapy to deplete B cells", "Interleukin-2 supplementation"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin replacement is the cornerstone of therapy for common variable immunodeficiency to prevent infections by providing passive immunity. Prophylactic antibiotics are adjunctive but not sufficient alone, while transplantation is reserved for severe cases with cellular defects. Rituximab and IL-2 are not standard for this humoral immunodeficiency.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 28-year-old man with established common variable immunodeficiency (CVID); markedly low IgG, IgA, IgM; absent responses to protein and polysaccharide vaccines; known TACI mutation; recurrent sinopulmonary infections; question asks for the most appropriate long-term management strategy. These features point to a primary humoral immunodeficiency for which standard of care is immunoglobulin replacement therapy.\\n\\nOption A (monthly IVIG) is clearly the standard cornerstone long-term therapy in CVID to prevent infections and complications. Option B (prophylactic TMP-SMX) may be used adjunctively but is not sufficient or standard as sole long-term management. Option C (HSCT) is generally not indicated for classic CVID with intact cellular immunity and is reserved for specific severe combined immunodeficiencies or life-threatening complications. Option D (rituximab) may be used for autoimmune/lymphoproliferative complications, not as primary long-term management. Option E (IL-2) has no established role in routine CVID management.\\n\\nNo internal contradictions or underspecification are present; one best answer is supported and matches the key.\\n\\nMinimal fix: Specify IVIG dose/route more precisely (e.g., “Regular immunoglobulin replacement therapy (intravenous or subcutaneous)”) to reflect modern practice, though current wording is acceptable.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 28-year-old man with established common variable immunodeficiency (CVID); markedly low IgG, IgA, IgM; absent responses to protein and polysaccharide vaccines; known TACI mutation; recurrent sinopulmonary infections; question asks for the most appropriate long-term management strategy. These features point to a primary humoral immunodeficiency for which standard of care is immunoglobulin replacement therapy.\n\nOption A (monthly IVIG) is clearly the standard cornerstone long-term therapy in CVID to prevent infections and complications. Option B (prophylactic TMP-SMX) may be used adjunctively but is not sufficient or standard as sole long-term management. Option C (HSCT) is generally not indicated for classic CVID with intact cellular immunity and is reserved for specific severe combined immunodeficiencies or life-threatening complications. Option D (rituximab) may be used for autoimmune/lymphoproliferative complications, not as primary long-term management. Option E (IL-2) has no established role in routine CVID management.\n\nNo internal contradictions or underspecification are present; one best answer is supported and matches the key.\n\nMinimal fix: Specify IVIG dose/route more precisely (e.g., “Regular immunoglobulin replacement therapy (intravenous or subcutaneous)”) to reflect modern practice, though current wording is acceptable.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-004", "question": "A 35-year-old traveler returns from sub-Saharan Africa with fever, chills, and myalgias. Blood smear shows ring forms and gametocytes consistent with Plasmodium falciparum. He is treated with artemether-lumefantrine, but 48 hours later, parasitemia persists at 3%. Genotyping reveals a mutation in the PfKelch13 gene. What is the most appropriate next therapeutic intervention?", "options": ["Switch to atovaquone-proguanil", "Add primaquine for gametocytocidal effect", "Initiate intravenous artesunate", "Administer doxycycline as monotherapy", "Use mefloquine as alternative therapy"], "answer": "C", "answer_index": 2, "explanation": "Persistent parasitemia with PfKelch13 mutation indicates artemisinin resistance, necessitating intravenous artesunate for rapid parasite clearance in severe or resistant falciparum malaria. Atovaquone-proguanil or mefloquine may face cross-resistance, while primaquine and doxycycline are not first-line for acute treatment failure. Artesunate is recommended by WHO for such cases.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed – C is not the best answer.\\nKey stem clues: Non-immune traveler, P falciparum, initially treated with oral artemether‑lumefantrine; 48 hours later parasitemia still 3% (no data on severity, organ dysfunction, or hyperparasitemia); PfKelch13 mutation indicating partial artemisinin resistance.\\nLogical issues: WHO guidance for artemisinin resistance recommends switching to an effective alternative ACT (e.g., atovaquone‑proguanil or mefloquine, depending on local resistance) when uncomplicated malaria fails artemisinin-based therapy. IV artesunate is indicated for severe malaria or very high parasitemia, which is not specified here. Thus, based on an uncomplicated case with treatment failure, option A (switch to atovaquone‑proguanil) is more appropriate than IV artesunate, making the keyed answer C misaligned with standard practice. Options B and D are adjunct/gametocytocidal or prophylactic, not definitive acute rescue. E is an alternative ACT but atovaquone‑proguanil generally preferred for travelers from much of Africa.\\nMedical accuracy issues: Overstates indication for IV artesunate solely due to Kelch13 mutation and modest persistent parasitemia.\\nMinimal fix: Specify severe malaria criteria (e.g., “parasitemia 10% with hypotension and confusion”) to justify IV artesunate as clearly correct, or change key to A and revise explanation accordingly.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed – C is not the best answer.\nKey stem clues: Non-immune traveler, P falciparum, initially treated with oral artemether‑lumefantrine; 48 hours later parasitemia still 3% (no data on severity, organ dysfunction, or hyperparasitemia); PfKelch13 mutation indicating partial artemisinin resistance.\nLogical issues: WHO guidance for artemisinin resistance recommends switching to an effective alternative ACT (e.g., atovaquone‑proguanil or mefloquine, depending on local resistance) when uncomplicated malaria fails artemisinin-based therapy. IV artesunate is indicated for severe malaria or very high parasitemia, which is not specified here. Thus, based on an uncomplicated case with treatment failure, option A (switch to atovaquone‑proguanil) is more appropriate than IV artesunate, making the keyed answer C misaligned with standard practice. Options B and D are adjunct/gametocytocidal or prophylactic, not definitive acute rescue. E is an alternative ACT but atovaquone‑proguanil generally preferred for travelers from much of Africa.\nMedical accuracy issues: Overstates indication for IV artesunate solely due to Kelch13 mutation and modest persistent parasitemia.\nMinimal fix: Specify severe malaria criteria (e.g., “parasitemia 10% with hypotension and confusion”) to justify IV artesunate as clearly correct, or change key to A and revise explanation accordingly.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-005", "question": "A 55-year-old man with metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation progresses on osimertinib. Tumor biopsy shows transformation to small cell histology. He has good performance status. What is the most appropriate systemic therapy?", "options": ["Continue osimertinib with added chemotherapy", "Switch to amivantamab", "Initiate etoposide and platinum-based chemotherapy", "Use mobocertinib as targeted therapy", "Administer immune checkpoint inhibitor monotherapy"], "answer": "C", "answer_index": 2, "explanation": "Transformation to small cell lung cancer in EGFR-mutant NSCLC requires treatment as small cell carcinoma with etoposide-platinum chemotherapy, which has shown responses in such cases. Continuing EGFR inhibitors is ineffective post-transformation, while amivantamab and mobocertinib target specific exon 20 insertions but not small cell histology. Immunotherapy has limited efficacy in transformed disease.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 55-year-old with metastatic EGFR exon 20–mutant NSCLC, progression on osimertinib, biopsy-proven transformation to small cell histology, good performance status, and a question asking for the most appropriate systemic therapy. Histologic transformation to small cell carcinoma in EGFR-mutant NSCLC is managed according to small cell lung cancer standards.\\nOption C (etoposide and platinum-based chemotherapy) aligns with standard first-line therapy for extensive-stage SCLC and is the established approach for EGFR-mutant NSCLC transformed to SCLC.\\nWhy other options are worse: A) Continuing osimertinib post-SCLC transformation is not standard; EGFR dependence is typically lost. B) Amivantamab is for EGFR exon 20–mutant NSCLC, not SCLC histology. D) Mobocertinib similarly targets EGFR exon 20 NSCLC, not transformed SCLC. E) ICI monotherapy has low efficacy in EGFR-mutant and in transformed SCLC; chemo is preferred.\\nMedical accuracy: The explanation correctly reflects current understanding of SCLC transformation and management; no major inaccuracies.\\nMinimal fix: Clarify in the stem that the small cell transformation is extensive-stage/metastatic (e.g., “biopsy of a metastatic lesion shows small cell carcinoma”) to tightly match the standard indication for etoposide–platinum therapy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 55-year-old with metastatic EGFR exon 20–mutant NSCLC, progression on osimertinib, biopsy-proven transformation to small cell histology, good performance status, and a question asking for the most appropriate systemic therapy. Histologic transformation to small cell carcinoma in EGFR-mutant NSCLC is managed according to small cell lung cancer standards.\nOption C (etoposide and platinum-based chemotherapy) aligns with standard first-line therapy for extensive-stage SCLC and is the established approach for EGFR-mutant NSCLC transformed to SCLC.\nWhy other options are worse: A) Continuing osimertinib post-SCLC transformation is not standard; EGFR dependence is typically lost. B) Amivantamab is for EGFR exon 20–mutant NSCLC, not SCLC histology. D) Mobocertinib similarly targets EGFR exon 20 NSCLC, not transformed SCLC. E) ICI monotherapy has low efficacy in EGFR-mutant and in transformed SCLC; chemo is preferred.\nMedical accuracy: The explanation correctly reflects current understanding of SCLC transformation and management; no major inaccuracies.\nMinimal fix: Clarify in the stem that the small cell transformation is extensive-stage/metastatic (e.g., “biopsy of a metastatic lesion shows small cell carcinoma”) to tightly match the standard indication for etoposide–platinum therapy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-006", "question": "A 12-year-old boy with hereditary angioedema type I presents with recurrent abdominal pain and facial swelling. Laboratory studies show C1 inhibitor level 20% of normal and low C4. He has breakthrough episodes despite prophylactic danazol. What is the most appropriate escalation in therapy?", "options": ["Switch to tranexamic acid prophylaxis", "Initiate subcutaneous C1 inhibitor replacement", "Add icatibant for on-demand treatment", "Use ecallantide for acute attacks", "Administer fresh frozen plasma infusions"], "answer": "B", "answer_index": 1, "explanation": "Subcutaneous C1 inhibitor replacement is effective for prophylaxis in hereditary angioedema with breakthrough on androgens, providing targeted replacement of the deficient protein. Tranexamic acid is less effective for type I, while icatibant and ecallantide are for acute treatment, not prophylaxis. Fresh frozen plasma carries risks and is not preferred for long-term use.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 12-year-old boy, hereditary angioedema type I (low C1-INH, low C4), already on prophylactic danazol but still having breakthrough attacks (recurrent abdominal pain, facial swelling). The question asks for escalation of *prophylactic* therapy. Current consensus favors targeted C1 inhibitor replacement (IV or SC) for long-term prophylaxis, especially when androgens are inadequate or undesirable. Option B (subcutaneous C1 inhibitor replacement) directly addresses this need and is guideline-consistent.\\nAlternatives: A (tranexamic acid) is less effective, generally second/third line in type I HAE. C and D (icatibant, ecallantide) are for on-demand acute attack treatment, not escalation of prophylaxis. E (FFP) may be used when specific agents unavailable, mainly for acute or short-term use; not preferred for long-term prophylaxis due to volume and viral risks.\\nMain medical accuracy: Aligned with modern HAE management; no major inaccuracies.\\nMinimal fix: Specify “He and his family prefer to discontinue androgen therapy due to side effects” or “despite maximal tolerated danazol” to further justify escalation to C1-INH prophylaxis and clarify the prophylaxis focus in the stem.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 12-year-old boy, hereditary angioedema type I (low C1-INH, low C4), already on prophylactic danazol but still having breakthrough attacks (recurrent abdominal pain, facial swelling). The question asks for escalation of *prophylactic* therapy. Current consensus favors targeted C1 inhibitor replacement (IV or SC) for long-term prophylaxis, especially when androgens are inadequate or undesirable. Option B (subcutaneous C1 inhibitor replacement) directly addresses this need and is guideline-consistent.\nAlternatives: A (tranexamic acid) is less effective, generally second/third line in type I HAE. C and D (icatibant, ecallantide) are for on-demand acute attack treatment, not escalation of prophylaxis. E (FFP) may be used when specific agents unavailable, mainly for acute or short-term use; not preferred for long-term prophylaxis due to volume and viral risks.\nMain medical accuracy: Aligned with modern HAE management; no major inaccuracies.\nMinimal fix: Specify “He and his family prefer to discontinue androgen therapy due to side effects” or “despite maximal tolerated danazol” to further justify escalation to C1-INH prophylaxis and clarify the prophylaxis focus in the stem.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-007", "question": "An 82-year-old woman with mild cognitive impairment presents with recurrent falls and orthostatic hypotension. She takes donepezil 10 mg daily. Autonomic testing shows sympathetic denervation. Brain MRI reveals hippocampal atrophy. What is the most likely underlying diagnosis contributing to her symptoms?", "options": ["Alzheimer disease with autonomic involvement", "Lewy body dementia", "Multiple system atrophy", "Vascular parkinsonism", "Progressive supranuclear palsy"], "answer": "B", "answer_index": 1, "explanation": "Lewy body dementia often presents with orthostatic hypotension due to autonomic dysfunction, recurrent falls, and cognitive impairment with hippocampal atrophy on MRI. Alzheimer disease rarely causes significant autonomic symptoms, while multiple system atrophy typically has more severe parkinsonism and cerebellar signs. Vascular parkinsonism and PSP lack prominent autonomic features.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: elderly woman, mild cognitive impairment, recurrent falls, orthostatic hypotension, autonomic testing showing sympathetic denervation, and MRI with hippocampal atrophy. Among neurodegenerative dementias, dementia with Lewy bodies (DLB) is strongly associated with autonomic dysfunction (including orthostatic hypotension) and falls in the context of cognitive impairment. Alzheimer disease can show hippocampal atrophy but has relatively limited autonomic involvement. Multiple system atrophy has prominent autonomic failure and sympathetic denervation but is typically characterized by more severe parkinsonism and/or cerebellar/UMN signs rather than a primary dementia picture; DLB better matches the cognitive profile in a patient already on donepezil. Vascular parkinsonism and progressive supranuclear palsy are not typically associated with marked autonomic failure or primary hippocampal atrophy. The explanation is somewhat simplistic (autonomic involvement in AD can occur, and hippocampal atrophy is not specific to DLB), but the pattern of dementia plus prominent autonomic failure and falls most strongly supports Lewy body dementia. Minimal fix: explicitly mention fluctuating cognition or parkinsonism to more strongly point to Lewy body dementia over other neurodegenerative causes.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: elderly woman, mild cognitive impairment, recurrent falls, orthostatic hypotension, autonomic testing showing sympathetic denervation, and MRI with hippocampal atrophy. Among neurodegenerative dementias, dementia with Lewy bodies (DLB) is strongly associated with autonomic dysfunction (including orthostatic hypotension) and falls in the context of cognitive impairment. Alzheimer disease can show hippocampal atrophy but has relatively limited autonomic involvement. Multiple system atrophy has prominent autonomic failure and sympathetic denervation but is typically characterized by more severe parkinsonism and/or cerebellar/UMN signs rather than a primary dementia picture; DLB better matches the cognitive profile in a patient already on donepezil. Vascular parkinsonism and progressive supranuclear palsy are not typically associated with marked autonomic failure or primary hippocampal atrophy. The explanation is somewhat simplistic (autonomic involvement in AD can occur, and hippocampal atrophy is not specific to DLB), but the pattern of dementia plus prominent autonomic failure and falls most strongly supports Lewy body dementia. Minimal fix: explicitly mention fluctuating cognition or parkinsonism to more strongly point to Lewy body dementia over other neurodegenerative causes.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-008", "question": "A 58-year-old man with IgA nephropathy and chronic kidney disease stage 4 develops hyperkalemia refractory to dietary restriction and loop diuretics. Serum potassium is 6.8 mEq/L with normal acid-base status. He is not on ACE inhibitors. What is the most appropriate pharmacologic intervention?", "options": ["Initiate sodium polystyrene sulfonate", "Start patiromer therapy", "Administer sodium zirconium cyclosilicate", "Use fludrocortisone acetate", "Prescribe sodium bicarbonate supplementation"], "answer": "D", "answer_index": 3, "explanation": "Fludrocortisone promotes potassium excretion in the distal tubule and is useful for hyperkalemia in hypoaldosteronism-like states in CKD without acidosis. Patiromer and zirconium are binders for chronic management but less effective in advanced CKD without dialysis. Polystyrene sulfonate has safety concerns, and bicarbonate is for acidotic states.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple defensible answers, possible miskey)\\nVerdict on keyed answer: Not uniquely determinable; D is debatable vs B/C.\\nKey stem clues: CKD stage 4, IgA nephropathy; persistent severe hyperkalemia (K⁺ 6.8) despite diet and loop diuretics; normal acid-base status; no ACEi; question asks for “most appropriate pharmacologic intervention.” No explicit hypoaldosteronism, type 4 RTA, or blood pressure/volume data.\\nMain logical issues: The explanation assumes a hypoaldosteronism-like state, but this is not stated. In stage 4 CKD, generalized decreased nephron mass and impaired K⁺ excretion are more typical than isolated hypoaldosteronism; mineralocorticoid responsiveness may be limited and can worsen hypertension/edema. Modern guidelines support patiromer or sodium zirconium cyclosilicate as chronic K⁺ binders in CKD patients with hyperkalemia; the rationale’s claim that they are “less effective in advanced CKD without dialysis” is not firmly evidence-based. Thus B or C are at least as defensible as D.\\nMain medical accuracy issues: Overstates limitations of patiromer/zirconium and underjustifies fludrocortisone as first-line in general CKD hyperkalemia without documented hypoaldosteronism.\\nMinimal fix: Explicitly state documented hypoaldosteronism/type 4 RTA with preserved volume status, or rekey to a potassium binder (e.g., B) and adjust explanation accordingly.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple defensible answers, possible miskey)\nVerdict on keyed answer: Not uniquely determinable; D is debatable vs B/C.\nKey stem clues: CKD stage 4, IgA nephropathy; persistent severe hyperkalemia (K⁺ 6.8) despite diet and loop diuretics; normal acid-base status; no ACEi; question asks for “most appropriate pharmacologic intervention.” No explicit hypoaldosteronism, type 4 RTA, or blood pressure/volume data.\nMain logical issues: The explanation assumes a hypoaldosteronism-like state, but this is not stated. In stage 4 CKD, generalized decreased nephron mass and impaired K⁺ excretion are more typical than isolated hypoaldosteronism; mineralocorticoid responsiveness may be limited and can worsen hypertension/edema. Modern guidelines support patiromer or sodium zirconium cyclosilicate as chronic K⁺ binders in CKD patients with hyperkalemia; the rationale’s claim that they are “less effective in advanced CKD without dialysis” is not firmly evidence-based. Thus B or C are at least as defensible as D.\nMain medical accuracy issues: Overstates limitations of patiromer/zirconium and underjustifies fludrocortisone as first-line in general CKD hyperkalemia without documented hypoaldosteronism.\nMinimal fix: Explicitly state documented hypoaldosteronism/type 4 RTA with preserved volume status, or rekey to a potassium binder (e.g., B) and adjust explanation accordingly.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-009", "question": "A 40-year-old woman with sickle cell disease presents with acute chest syndrome. She has hypoxia, fever, and new infiltrates on chest X-ray. Hemoglobin is 6.5 g/dL, reticulocytes 12%. Transfusion is initiated, but she develops worsening dyspnea and hypertension. What is the most likely complication?", "options": ["Transfusion-related acute lung injury", "Hyperhemolysis syndrome", "Transfusion-associated circulatory overload", "Delayed hemolytic transfusion reaction", "Acute hemolytic reaction from alloantibodies"], "answer": "C", "answer_index": 2, "explanation": "Transfusion-associated circulatory overload is common in sickle cell patients with acute chest syndrome due to volume sensitivity and underlying cardiac strain, presenting with hypertension and dyspnea. TRALI typically involves hypotension, while hyperhemolysis shows hemolysis without volume overload. Delayed reactions occur later, and acute hemolysis presents with fever and back pain.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Sickle cell disease with acute chest syndrome; transfusion started; soon after, patient develops worsening dyspnea and *hypertension*. No mention of hypotension, fever, back pain, hemoglobinuria, or hemolysis labs; timing is acute and closely linked to transfusion.\\nReasoning: The vignette asks for the most likely transfusion complication. Acute dyspnea with *hypertension* and volume sensitivity is characteristic of transfusion-associated circulatory overload (TACO). TRALI more often presents with acute hypoxemia, bilateral infiltrates, and classically normotension or hypotension rather than hypertension. Hyperhemolysis syndrome and delayed hemolytic transfusion reaction are typically delayed by days and feature hemolysis, not acute hypertensive dyspnea from volume overload. Acute hemolytic reaction from alloantibodies would present during/soon after transfusion but typically with fever, chills, flank/back pain, DIC, and hemoglobinuria—not isolated hypertension and dyspnea.\\nLogical issues: None significant; stem gives adequate discriminating hemodynamic clue (hypertension) and timing. Single best answer is clearly C, matching the key.\\nMain medical accuracy issues: Minor—TACO is not uniquely more “common” in sickle cell but they are volume-sensitive; description is acceptable.\\nMinimal fix: Specify exam findings of pulmonary edema or elevated JVP to further distinguish TACO from TRALI.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Sickle cell disease with acute chest syndrome; transfusion started; soon after, patient develops worsening dyspnea and *hypertension*. No mention of hypotension, fever, back pain, hemoglobinuria, or hemolysis labs; timing is acute and closely linked to transfusion.\nReasoning: The vignette asks for the most likely transfusion complication. Acute dyspnea with *hypertension* and volume sensitivity is characteristic of transfusion-associated circulatory overload (TACO). TRALI more often presents with acute hypoxemia, bilateral infiltrates, and classically normotension or hypotension rather than hypertension. Hyperhemolysis syndrome and delayed hemolytic transfusion reaction are typically delayed by days and feature hemolysis, not acute hypertensive dyspnea from volume overload. Acute hemolytic reaction from alloantibodies would present during/soon after transfusion but typically with fever, chills, flank/back pain, DIC, and hemoglobinuria—not isolated hypertension and dyspnea.\nLogical issues: None significant; stem gives adequate discriminating hemodynamic clue (hypertension) and timing. Single best answer is clearly C, matching the key.\nMain medical accuracy issues: Minor—TACO is not uniquely more “common” in sickle cell but they are volume-sensitive; description is acceptable.\nMinimal fix: Specify exam findings of pulmonary edema or elevated JVP to further distinguish TACO from TRALI.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-010", "question": "A 50-year-old man with rheumatoid arthritis on methotrexate develops pancytopenia. Bone marrow biopsy shows hypocellularity with absent megakaryocytes. Autoantibody testing is negative. Genetic analysis reveals shortened telomeres and a TERT mutation. What is the most appropriate definitive treatment?", "options": ["Switch to alternative immunosuppressive therapy", "Initiate danazol for telomere elongation", "Perform allogeneic hematopoietic stem cell transplant", "Administer eltrombopag as thrombopoietin mimetic", "Use anti-thymocyte globulin with cyclosporine"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic stem cell transplant is curative for dyskeratosis congenita-related aplastic anemia due to telomere biology disorders, addressing the underlying genetic defect. Danazol may stabilize telomeres temporarily but is not definitive, while immunosuppressives like ATG are for acquired aplasia. Eltrombopag stimulates residual marrow but does not correct the genetic issue.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 50-year-old man; rheumatoid arthritis on methotrexate; develops pancytopenia; bone marrow hypocellular with absent megakaryocytes; autoantibody testing negative (argues against classic immune aplastic anemia); genetic analysis shows shortened telomeres and TERT mutation (telomere biology disorder / dyskeratosis-congenita–type inherited aplastic anemia). The question asks for the most appropriate definitive treatment. For inherited telomere biology–related aplastic anemia, allogeneic hematopoietic stem cell transplant is the only curative/definitive therapy, making C the best answer.\\nAlternatives: A (switch immunosuppression) addresses methotrexate toxicity, but clear telomere mutation indicates primary marrow failure, not drug effect. B (danazol) can improve counts and telomere length but is not definitive/curative. D (eltrombopag) may stimulate residual marrow but does not fix the genetic defect. E (ATG + cyclosporine) is preferred for acquired idiopathic aplastic anemia, less so for established germline TERT mutation.\\nMain medical-accuracy issues: Minor—TERT-associated disease is an inherited marrow failure; transplant does not correct the genetic lesion in somatic tissues but is considered definitive for marrow failure. Minimal fix: Reword explanation to say “curative for the bone-marrow failure” rather than “addressing the underlying genetic defect.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 50-year-old man; rheumatoid arthritis on methotrexate; develops pancytopenia; bone marrow hypocellular with absent megakaryocytes; autoantibody testing negative (argues against classic immune aplastic anemia); genetic analysis shows shortened telomeres and TERT mutation (telomere biology disorder / dyskeratosis-congenita–type inherited aplastic anemia). The question asks for the most appropriate definitive treatment. For inherited telomere biology–related aplastic anemia, allogeneic hematopoietic stem cell transplant is the only curative/definitive therapy, making C the best answer.\nAlternatives: A (switch immunosuppression) addresses methotrexate toxicity, but clear telomere mutation indicates primary marrow failure, not drug effect. B (danazol) can improve counts and telomere length but is not definitive/curative. D (eltrombopag) may stimulate residual marrow but does not fix the genetic defect. E (ATG + cyclosporine) is preferred for acquired idiopathic aplastic anemia, less so for established germline TERT mutation.\nMain medical-accuracy issues: Minor—TERT-associated disease is an inherited marrow failure; transplant does not correct the genetic lesion in somatic tissues but is considered definitive for marrow failure. Minimal fix: Reword explanation to say “curative for the bone-marrow failure” rather than “addressing the underlying genetic defect.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-011", "question": "A 25-year-old man with HIV on antiretroviral therapy presents with headache and seizures. CSF analysis shows lymphocytic pleocytosis, elevated protein, and positive India ink stain. MRI reveals multiple ring-enhancing lesions. CD4 count is 150 cells/μL. What is the most appropriate initial management?", "options": ["Start amphotericin B and flucytosine induction", "Initiate pyrimethamine and sulfadiazine", "Administer acyclovir for herpes encephalitis", "Use intravenous ceftriaxone for bacterial meningitis", "Prescribe albendazole for neurocysticercosis"], "answer": "A", "answer_index": 0, "explanation": "Cryptococcal meningitis in HIV presents with India ink-positive CSF and ring-enhancing lesions, requiring induction with amphotericin B and flucytosine for clearance. Toxoplasmosis lacks India ink positivity, while herpes, bacterial, and parasitic etiologies do not match the CSF findings. Prompt antifungal therapy reduces mortality in this setting.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: HIV-positive patient (CD4 150) with headache and seizures; CSF shows lymphocytic pleocytosis, elevated protein, and positive India ink stain; MRI shows multiple ring-enhancing lesions. India ink positivity is classic for Cryptococcus neoformans. In HIV, cryptococcal meningoencephalitis can produce parenchymal lesions (cryptococcomas) that may appear ring-enhancing, so this does not contradict the diagnosis. Therefore, initial management is induction therapy with amphotericin B plus flucytosine.\\nAlternative choices: B (pyrimethamine-sulfadiazine) is for Toxoplasma encephalitis, which would not have India ink–positive CSF. C (acyclovir) is for HSV encephalitis, typically with different CSF profile and no India ink positivity. D (ceftriaxone) targets bacterial meningitis, which would more often show neutrophilic CSF and negative India ink. E (albendazole) is for neurocysticercosis, again not associated with India ink–positive CSF.\\nMain medical issues: Minor nuance that ring-enhancing lesions are more typical for toxoplasmosis but can occur with cryptococcomas; still, the India ink finding is decisive.\\nMinimal fix: Explicitly mention CSF cryptococcal antigen positivity to reinforce the cryptococcal diagnosis and reduce ambiguity about imaging findings.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: HIV-positive patient (CD4 150) with headache and seizures; CSF shows lymphocytic pleocytosis, elevated protein, and positive India ink stain; MRI shows multiple ring-enhancing lesions. India ink positivity is classic for Cryptococcus neoformans. In HIV, cryptococcal meningoencephalitis can produce parenchymal lesions (cryptococcomas) that may appear ring-enhancing, so this does not contradict the diagnosis. Therefore, initial management is induction therapy with amphotericin B plus flucytosine.\nAlternative choices: B (pyrimethamine-sulfadiazine) is for Toxoplasma encephalitis, which would not have India ink–positive CSF. C (acyclovir) is for HSV encephalitis, typically with different CSF profile and no India ink positivity. D (ceftriaxone) targets bacterial meningitis, which would more often show neutrophilic CSF and negative India ink. E (albendazole) is for neurocysticercosis, again not associated with India ink–positive CSF.\nMain medical issues: Minor nuance that ring-enhancing lesions are more typical for toxoplasmosis but can occur with cryptococcomas; still, the India ink finding is decisive.\nMinimal fix: Explicitly mention CSF cryptococcal antigen positivity to reinforce the cryptococcal diagnosis and reduce ambiguity about imaging findings.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-012", "question": "A 65-year-old woman with triple-negative breast cancer metastatic to liver and bones receives paclitaxel. After the third cycle, she develops grade 3 neuropathy and pancytopenia. Germline testing reveals a PALB2 mutation. What is the most appropriate adjustment to her treatment regimen?", "options": ["Switch to eribulin monotherapy", "Add olaparib as PARP inhibitor", "Initiate sacituzumab govitecan", "Use capecitabine as oral chemotherapy", "Administer talazoparib with dose reduction"], "answer": "B", "answer_index": 1, "explanation": "PALB2 mutations confer sensitivity to PARP inhibitors like olaparib in metastatic breast cancer, offering a targeted approach after chemotherapy toxicity. Eribulin and capecitabine are chemotherapies without targeting the mutation, while sacituzumab is for later lines. Talazoparib is another PARP but not first-choice here.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (Multiple answers defensible), with component of possible K.\\nVerdict on keyed answer: Not uniquely determinable; B is reasonable but E is also defensible.\\nKey stem clues: Metastatic triple‑negative breast cancer; prior paclitaxel with grade 3 neuropathy and pancytopenia (needs to change regimen); germline PALB2 mutation (homologous recombination deficiency, PARP‑sensitive). Question asks for most appropriate adjustment, i.e., next systemic therapy.\\nBoth olaparib (B) and talazoparib (E) are PARP inhibitors with data and regulatory precedent for germline BRCA‑mutated HER2‑negative metastatic breast cancer and emerging acceptance for germline PALB2; the stem gives no reason to prefer one specific PARP agent. The explanation that talazoparib is “not first‑choice here” is not supported by guideline-level hierarchy; choice E’s mention of dose reduction could even be seen as safer in a pancytopenic patient. Thus, two targeted, mutation‑directed options are similarly defensible.\\nThe other choices are less appropriate because they are non‑targeted cytotoxics (A, D) or an antibody–drug conjugate generally used after ≥2 prior regimens (C).\\nMinimal fix: Specify \\\"Which PARP inhibitor has strongest guideline support/phase III data for this scenario?\\\" and make all other PARP options non‑PARP agents, or remove talazoparib from the options.\",\n  \"medical_accuracy_score\":    \"4\",\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible), with component of possible K.\nVerdict on keyed answer: Not uniquely determinable; B is reasonable but E is also defensible.\nKey stem clues: Metastatic triple‑negative breast cancer; prior paclitaxel with grade 3 neuropathy and pancytopenia (needs to change regimen); germline PALB2 mutation (homologous recombination deficiency, PARP‑sensitive). Question asks for most appropriate adjustment, i.e., next systemic therapy.\nBoth olaparib (B) and talazoparib (E) are PARP inhibitors with data and regulatory precedent for germline BRCA‑mutated HER2‑negative metastatic breast cancer and emerging acceptance for germline PALB2; the stem gives no reason to prefer one specific PARP agent. The explanation that talazoparib is “not first‑choice here” is not supported by guideline-level hierarchy; choice E’s mention of dose reduction could even be seen as safer in a pancytopenic patient. Thus, two targeted, mutation‑directed options are similarly defensible.\nThe other choices are less appropriate because they are non‑targeted cytotoxics (A, D) or an antibody–drug conjugate generally used after ≥2 prior regimens (C).\nMinimal fix: Specify \"Which PARP inhibitor has strongest guideline support/phase III data for this scenario?\" and make all other PARP options non‑PARP agents, or remove talazoparib from the options.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-013", "question": "A 4-year-old girl with Wiskott-Aldrich syndrome presents with eczema, thrombocytopenia, and recurrent infections. She has low IgM and elevated IgE. Hematopoietic stem cell transplant is planned, but she develops hives after platelet transfusion. What is the most likely immunologic mechanism?", "options": ["IgA deficiency leading to anti-IgA antibodies", "Type I hypersensitivity to platelet antigens", "Complement activation by immune complexes", "IgE-mediated reaction to plasma proteins", "Delayed T-cell mediated hypersensitivity"], "answer": "D", "answer_index": 3, "explanation": "Elevated IgE in Wiskott-Aldrich syndrome predisposes to allergic reactions, including IgE-mediated hives from plasma proteins in transfusions. IgA deficiency is not typical, while type I hypersensitivity to antigens is less specific. Complement or T-cell mechanisms do not explain acute urticaria.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known Wiskott–Aldrich syndrome (eczema, thrombocytopenia, recurrent infections, low IgM, high IgE), exposure to platelet transfusion, and development of acute hives (urticaria) during/after transfusion. Urticaria temporally related to transfusion points to an acute allergic transfusion reaction, which is IgE-mediated against donor plasma proteins.\\nOption D (“IgE-mediated reaction to plasma proteins”) precisely describes the standard mechanism of an allergic transfusion reaction producing hives. Option A involves anti-IgA in IgA-deficient patients, not typical for Wiskott–Aldrich and would more often cause anaphylaxis than simple hives. Option B is vague and less accurate than D; standard teaching is that plasma proteins, not platelet surface antigens, mediate common urticarial transfusion reactions. Option C (immune complex/complement) fits serum sickness-like or some hemolytic reactions, not isolated hives. Option E (delayed T-cell mediated) would not cause immediate urticaria.\\nThe item cleanly supports a unique best answer and the key aligns with accepted pathophysiology. Main medical inaccuracy is minor: Wiskott–Aldrich’s elevated IgE doesn’t uniquely predispose beyond general atopy. Minimal fix: remove or soften the causal link to elevated IgE in the explanation.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known Wiskott–Aldrich syndrome (eczema, thrombocytopenia, recurrent infections, low IgM, high IgE), exposure to platelet transfusion, and development of acute hives (urticaria) during/after transfusion. Urticaria temporally related to transfusion points to an acute allergic transfusion reaction, which is IgE-mediated against donor plasma proteins.\nOption D (“IgE-mediated reaction to plasma proteins”) precisely describes the standard mechanism of an allergic transfusion reaction producing hives. Option A involves anti-IgA in IgA-deficient patients, not typical for Wiskott–Aldrich and would more often cause anaphylaxis than simple hives. Option B is vague and less accurate than D; standard teaching is that plasma proteins, not platelet surface antigens, mediate common urticarial transfusion reactions. Option C (immune complex/complement) fits serum sickness-like or some hemolytic reactions, not isolated hives. Option E (delayed T-cell mediated) would not cause immediate urticaria.\nThe item cleanly supports a unique best answer and the key aligns with accepted pathophysiology. Main medical inaccuracy is minor: Wiskott–Aldrich’s elevated IgE doesn’t uniquely predispose beyond general atopy. Minimal fix: remove or soften the causal link to elevated IgE in the explanation.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-014", "question": "A 78-year-old man with frailty and multimorbidity is admitted for pneumonia. He has a history of recurrent Clostridium difficile infections. Stool testing is positive for toxin. He completed vancomycin taper 2 weeks ago. What is the most appropriate treatment considering his geriatric status?", "options": ["Repeat oral vancomycin course", "Initiate fidaxomicin therapy", "Administer bezlotoxumab infusion", "Perform fecal microbiota transplant", "Use metronidazole as alternative"], "answer": "C", "answer_index": 2, "explanation": "Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, reduces recurrence in high-risk elderly patients without altering gut flora, ideal for frail geriatrics. Fidaxomicin is effective but costly, while repeat vancomycin increases resistance risk. Transplant is invasive, and metronidazole is inferior for recurrences.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible as written)\\nVerdict on keyed answer: No defensible answer\\nKey stem clues: 78-year-old, frail, multimorbid; admitted with pneumonia; recurrent C. difficile infection; stool toxin positive; just completed a vancomycin taper 2 weeks ago; question asks for “most appropriate treatment considering his geriatric status.”\\nMain logical/clinical issues: For a patient with multiple CDI recurrences shortly after a vancomycin taper, current guidelines recommend another standard-of-care antibiotic regimen (e.g., fidaxomicin, or vancomycin with pulse/taper, or FMT for multiple recurrences). Bezlotoxumab is an adjunctive prevention agent and is not used alone as primary treatment, yet all options are monotherapies. Thus C (bezlotoxumab) is inappropriate as sole “treatment” and not guideline-concordant. Fidaxomicin (B) is guideline-preferred for recurrence, including in older frail adults, so the explanation’s dismissal on cost grounds is not a standard board-style reason to avoid it. No option cleanly reflects best practice, so no single best is defensible.\\nMinimal fix: Change option C to “Oral fidaxomicin plus adjunctive bezlotoxumab” and adjust the key to that, or reword the stem to ask specifically about “adjunctive therapy to reduce recurrence risk,” making bezlotoxumab clearly appropriate.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible as written)\nVerdict on keyed answer: No defensible answer\nKey stem clues: 78-year-old, frail, multimorbid; admitted with pneumonia; recurrent C. difficile infection; stool toxin positive; just completed a vancomycin taper 2 weeks ago; question asks for “most appropriate treatment considering his geriatric status.”\nMain logical/clinical issues: For a patient with multiple CDI recurrences shortly after a vancomycin taper, current guidelines recommend another standard-of-care antibiotic regimen (e.g., fidaxomicin, or vancomycin with pulse/taper, or FMT for multiple recurrences). Bezlotoxumab is an adjunctive prevention agent and is not used alone as primary treatment, yet all options are monotherapies. Thus C (bezlotoxumab) is inappropriate as sole “treatment” and not guideline-concordant. Fidaxomicin (B) is guideline-preferred for recurrence, including in older frail adults, so the explanation’s dismissal on cost grounds is not a standard board-style reason to avoid it. No option cleanly reflects best practice, so no single best is defensible.\nMinimal fix: Change option C to “Oral fidaxomicin plus adjunctive bezlotoxumab” and adjust the key to that, or reword the stem to ask specifically about “adjunctive therapy to reduce recurrence risk,” making bezlotoxumab clearly appropriate.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}]